{"id":8284,"date":"2026-07-24T17:15:36","date_gmt":"2026-07-24T14:15:36","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=8284"},"modified":"2026-07-24T17:26:49","modified_gmt":"2026-07-24T14:26:49","slug":"sarcomatrix-s969-first-human-trial-2027","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/sarcomatrix-s969-first-human-trial-2027\/","title":{"rendered":"Sarcomatrix, Duchenne Kas Distrofisi i\u00e7in S-969'un \u0130lk \u0130nsan Denemesini 2027'de Ger\u00e7ekle\u015ftirmeyi Planl\u0131yor"},"content":{"rendered":"<p class=\"wp-block-paragraph\"><strong>Duchenne kas distrofisi (DMD) hastal\u0131\u011f\u0131ndan etkilenen aileler i\u00e7in her yeni klinik geli\u015fme umut kayna\u011f\u0131d\u0131r.<\/strong> Pek \u00e7ok umut vadeden tedavi y\u00f6ntemi laboratuvarda geli\u015ftirilmeye ba\u015flansa da, ger\u00e7ek test insanlar \u00fczerinde de\u011ferlendirildiklerinde ortaya \u00e7\u0131kar. <strong>Sarcomatrix Therapeutics, deneysel ilac\u0131 S-969 ile bu \u00f6nemli ad\u0131m\u0131 atmaya haz\u0131rlan\u0131yor ve 2027&#039;de ilk insan denemesine yol a\u00e7abilecek iddial\u0131 bir yol haritas\u0131 a\u00e7\u0131klad\u0131.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u015eirketin geli\u015ftirme takvimine g\u00f6re, Sarcomatrix, 2027 y\u0131l\u0131n\u0131n ilk \u00e7eyre\u011finde ABD G\u0131da ve \u0130la\u00e7 \u0130daresi&#039;ne (FDA) Ara\u015ft\u0131rma Ama\u00e7l\u0131 Yeni \u0130la\u00e7 (IND) ba\u015fvurusu (FDA) yapmay\u0131 planl\u0131yor.<\/strong> D\u00fczenleyici kurumlar \u00e7al\u0131\u015fmay\u0131 onaylarsa, \u015firket 2027&#039;nin ikinci \u00e7eyre\u011finde Avustralya&#039;n\u0131n Melbourne kentindeki Nucleus Network&#039;te insanlarda ilk doz uygulamas\u0131na ba\u015flamay\u0131 bekliyor. Tedavinin biyolojik aktivite g\u00f6sterip g\u00f6stermedi\u011fini ve etkinli\u011fe dair erken belirtileri g\u00f6steren ilk verilerin 2028&#039;in sonlar\u0131nda elde edilmesi bekleniyor.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu zaman \u00e7izelgesi \u00f6nemli bir d\u00f6n\u00fcm noktas\u0131n\u0131 temsil etse de, bunlar\u0131n garanti de\u011fil, geli\u015ftirme hedefleri oldu\u011funu anlamak da ayn\u0131 derecede \u00f6nemlidir. \u0130la\u00e7 geli\u015ftirme uzun bir s\u00fcre\u00e7tir ve bir\u00e7ok deneysel tedavi gecikmeler ya\u015far veya klinik testler s\u0131ras\u0131nda yeterli g\u00fcvenlik veya etkinli\u011fi g\u00f6steremez.<\/p>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>\u0130\u00e7indekiler<\/h2><nav><ul><li><a href=\"#why-is-s-969-different\">S-969&#039;un Farkl\u0131l\u0131\u011f\u0131 Nedir?<\/a><\/li><li><a href=\"#from-laboratory-research-to-human-studies\">Laboratuvar Ara\u015ft\u0131rmalar\u0131ndan \u0130nsan \u00c7al\u0131\u015fmalar\u0131na<\/a><\/li><li><a href=\"#what-will-families-learn-by-late-2028\">Aileler 2028 y\u0131l\u0131n\u0131n sonuna kadar neler \u00f6\u011frenecek?<\/a><\/li><li><a href=\"#a-growing-pipeline-beyond-gene-therapy\">Gen Terapisinin \u00d6tesinde B\u00fcy\u00fcyen Bir Geli\u015ftirme S\u00fcreci<\/a><\/li><li><a href=\"#financial-and-scientific-foundation\">Finansal ve Bilimsel Vak\u0131f<\/a><\/li><li><a href=\"#looking-ahead\">Gelece\u011fe Bak\u0131\u015f<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<h2 id=\"why-is-s-969-different\" class=\"wp-block-heading\">S-969&#039;un Farkl\u0131l\u0131\u011f\u0131 Nedir?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Duchenne kas distrofisi i\u00e7in \u015fu anda geli\u015ftirilmekte olan tedavilerin \u00e7o\u011fu, belirli genetik mutasyonlar\u0131 d\u00fczeltmeye odaklanmaktad\u0131r. DMD, distrofin genindeki binlerce farkl\u0131 mutasyondan kaynakland\u0131\u011f\u0131 i\u00e7in, bu tedavilerin \u00e7o\u011fu yaln\u0131zca nispeten k\u00fc\u00e7\u00fck hasta gruplar\u0131na fayda sa\u011flamaktad\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Sarcomatrix farkl\u0131 bir strateji izliyor.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>S-969, kusurlu distrofin genini onarmak yerine, kas liflerini stabilize etmeye ve kas\u0131n kendi onar\u0131m mekanizmalar\u0131n\u0131 desteklemeye yard\u0131mc\u0131 olan alfa-7 beta-1 integrin ad\u0131 verilen do\u011fal olarak olu\u015fan bir proteini hedef al\u0131r.<\/strong> Tedavi, hastan\u0131n spesifik genetik mutasyonundan ba\u011f\u0131ms\u0131z olarak kas dokusunu g\u00fc\u00e7lendirerek mutasyona duyars\u0131z olacak \u015fekilde tasarlanm\u0131\u015ft\u0131r; bu da \u00e7ok daha geni\u015f bir Duchenne pop\u00fclasyonuna fayda sa\u011flama potansiyeline sahip oldu\u011fu anlam\u0131na gelir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Bir di\u011fer \u00f6nemli \u00f6zelli\u011fi ise uygulama y\u00f6ntemidir. Damar i\u00e7i inf\u00fczyon gerektiren gen terapilerinin aksine, S-969 g\u00fcnde bir kez al\u0131nan oral bir hap olarak geli\u015ftirilmektedir; bu da, e\u011fer sonunda g\u00fcvenli ve etkili oldu\u011fu kan\u0131tlan\u0131rsa, tedaviyi daha kolay hale getirebilir.<\/strong><\/p>\n\n\n\n<h2 id=\"from-laboratory-research-to-human-studies\" class=\"wp-block-heading\">Laboratuvar Ara\u015ft\u0131rmalar\u0131ndan \u0130nsan \u00c7al\u0131\u015fmalar\u0131na<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Sarcomatrix, klinik \u00f6ncesi a\u015famada olan bir biyoteknoloji \u015firketidir.<\/strong> Bu, S-969&#039;un hen\u00fcz insan g\u00f6n\u00fcll\u00fcler \u00fczerinde test edilmedi\u011fi anlam\u0131na gelir. Yeni bir ila\u00e7 hastalara ula\u015fmadan \u00f6nce, ara\u015ft\u0131rmac\u0131lar\u0131n kabul edilebilir bir g\u00fcvenlik profili g\u00f6stermek i\u00e7in kapsaml\u0131 laboratuvar \u00e7al\u0131\u015fmalar\u0131 ve hayvan testleri tamamlamalar\u0131 gerekir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Yeterli preklinik kan\u0131t topland\u0131ktan sonra, \u015firketler klinik denemelere ba\u015flama izni almak i\u00e7in FDA&#039;ye bir IND ba\u015fvurusu sunarlar. Onayland\u0131\u011f\u0131 takdirde, Faz 1 \u00e7al\u0131\u015fmalar\u0131 \u00f6ncelikle g\u00fcvenli\u011fi, tolerans\u0131, dozaj\u0131 ve ilac\u0131n insan v\u00fccudunda nas\u0131l davrand\u0131\u011f\u0131n\u0131 de\u011ferlendirir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Melbourne&#039;deki Nucleus Network&#039;te planlanan \u00e7al\u0131\u015fma, laboratuvar biliminden klinik t\u0131bba ge\u00e7i\u015fin bu kritik a\u015famas\u0131n\u0131 temsil etmektedir.<\/strong> Bu a\u015famada elde edilecek ba\u015far\u0131, ara\u015ft\u0131rmac\u0131lar\u0131n S-969&#039;un Duchenne kas distrofisi olan ki\u015filerde nas\u0131l performans g\u00f6sterdi\u011fine dair ilk ger\u00e7ek d\u00fcnya verilerini toplamalar\u0131na olanak sa\u011flayacakt\u0131r.<\/p>\n\n\n\n<h2 id=\"what-will-families-learn-by-late-2028\" class=\"wp-block-heading\">Aileler 2028 y\u0131l\u0131n\u0131n sonuna kadar neler \u00f6\u011frenecek?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Bir\u00e7ok aile, 2028 y\u0131l\u0131n\u0131n sonlar\u0131nda a\u00e7\u0131klanmas\u0131 beklenen verilerin asl\u0131nda ne anlama geldi\u011fini merak edebilir.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u0130lk sonu\u00e7lar, tedavinin etkili oldu\u011funun kan\u0131tland\u0131\u011f\u0131 veya onaylanmaya haz\u0131r oldu\u011fu anlam\u0131na gelmez. Bunun yerine, erken klinik veriler genellikle birka\u00e7 \u00f6nemli sorunun yan\u0131tlanmas\u0131na yard\u0131mc\u0131 olur:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Bu ila\u00e7 hastalar i\u00e7in g\u00fcvenli mi?<\/li>\n\n\n\n<li>Ciddi yan etkileri var m\u0131?<\/li>\n\n\n\n<li>\u0130la\u00e7, hedeflenen biyolojik hedefe ula\u015f\u0131yor mu?<\/li>\n\n\n\n<li>Kas fonksiyonunda veya kas biyolojisinde iyile\u015fme olabilece\u011fine dair erken belirtiler var m\u0131?<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Bu ilk sonu\u00e7lar umut verici olsa bile, d\u00fczenleyici kurumlar\u0131n tedaviyi onaylamay\u0131 d\u00fc\u015f\u00fcnmeden \u00f6nce daha b\u00fcy\u00fck \u00e7apl\u0131 \u00e7al\u0131\u015fmalara ihtiya\u00e7 duyulacakt\u0131r.<\/p>\n\n\n\n<h2 id=\"a-growing-pipeline-beyond-gene-therapy\" class=\"wp-block-heading\">Gen Terapisinin \u00d6tesinde B\u00fcy\u00fcyen Bir Geli\u015ftirme S\u00fcreci<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Gen terapisi son y\u0131llarda Duchenne ara\u015ft\u0131rmalar\u0131nda devrim yaratt\u0131, ancak bilim insanlar\u0131 giderek artan bir \u015fekilde tek bir yakla\u015f\u0131m\u0131n hastal\u0131kla ilgili her zorlu\u011fu \u00e7\u00f6zmesinin m\u00fcmk\u00fcn olmad\u0131\u011f\u0131n\u0131 kabul ediyor.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">S-969 gibi mutasyondan ba\u011f\u0131ms\u0131z tedaviler, altta yatan genetik mutasyondan ba\u011f\u0131ms\u0131z olarak kas stabilitesini iyile\u015ftirerek mevcut tedavileri tamamlayabilir. S-969, distrofin genini de\u011fi\u015ftirmeye \u00e7al\u0131\u015fmad\u0131\u011f\u0131 i\u00e7in, Duchenne kas distrofisinin \u00f6tesinde, Becker kas distrofisi ve baz\u0131 uzuv ku\u015fa\u011f\u0131 kas distrofisi t\u00fcrleri de dahil olmak \u00fczere potansiyel uygulamalara sahip olabilir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu olas\u0131l\u0131klar\u0131n ger\u00e7e\u011fe d\u00f6n\u00fc\u015f\u00fcp d\u00f6n\u00fc\u015fmeyece\u011fi tamamen gelecekteki klinik deneme sonu\u00e7lar\u0131na ba\u011fl\u0131 olacakt\u0131r.<\/p>\n\n\n\n<h2 id=\"financial-and-scientific-foundation\" class=\"wp-block-heading\">Finansal ve Bilimsel Vak\u0131f<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Sarcomatrix projesi, ABD Ulusal Sa\u011fl\u0131k Enstit\u00fcleri (NIH) deste\u011fi de dahil olmak \u00fczere yat\u0131r\u0131mc\u0131lardan ve ara\u015ft\u0131rma hibelerinden yakla\u015f\u0131k 8,9 milyon ABD dolar\u0131 tutar\u0131nda fon sa\u011flamay\u0131 ba\u015fard\u0131.<\/strong> \u015eirketin k\u00f6keni de Nevada \u00dcniversitesi, Reno&#039;da y\u00fcr\u00fct\u00fclen ara\u015ft\u0131rmalara dayanmaktad\u0131r; temel bilimsel \u00e7al\u0131\u015fmalar\u0131n b\u00fcy\u00fck bir k\u0131sm\u0131 burada geli\u015ftirilmi\u015ftir. <strong>Bildirildi\u011fine g\u00f6re 75&#039;ten fazla patent ba\u015fvurusu yap\u0131lm\u0131\u015f olup, S-969 i\u00e7in Yetim \u0130la\u00e7 Stat\u00fcs\u00fc ba\u015fvurusu \u015fu anda i\u015flem a\u015famas\u0131ndad\u0131r.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu ba\u015far\u0131lar \u015firketin bilimsel temelini g\u00fc\u00e7lendirse de, d\u00fczenleyici onay\u0131n\u0131 garanti etmez.<\/p>\n\n\n\n<h2 id=\"looking-ahead\" class=\"wp-block-heading\">Gelece\u011fe Bak\u0131\u015f<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Duchenne kas distrofisi toplulu\u011fu i\u00e7in \u00f6n\u00fcm\u00fczdeki iki y\u0131l yak\u0131ndan takip edilecek. E\u011fer Sarcomatrix, FDA ba\u015fvurusunu 2027&#039;nin ba\u015flar\u0131nda ba\u015far\u0131yla sunar ve ayn\u0131 y\u0131l\u0131n sonlar\u0131na do\u011fru hastalara doz vermeye ba\u015flarsa, aileler 2028&#039;in sonuna do\u011fru ilk anlaml\u0131 klinik bilgilere ula\u015fabilirler.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu zaman \u00e7izelgesi, klinik geli\u015ftirmenin yaln\u0131zca ba\u015flang\u0131c\u0131n\u0131 temsil etmektedir. Bununla birlikte, laboratuvar ara\u015ft\u0131rmalar\u0131ndan insan \u00e7al\u0131\u015fmalar\u0131na ge\u00e7mek, herhangi bir deneysel tedavinin ula\u015fabilece\u011fi en \u00f6nemli kilometre ta\u015flar\u0131ndan biridir. S-969&#039;un nihayetinde gelecekte bir tedavi olup olmayaca\u011f\u0131 bilinmemektedir, ancak ilerlemesi, Duchenne kas distrofisi ile ya\u015fayan bireyler i\u00e7in sonu\u00e7lar\u0131 iyile\u015ftirmeyi ama\u00e7layan yenilik\u00e7i, mutasyondan ba\u011f\u0131ms\u0131z yakla\u015f\u0131mlar\u0131n s\u00fcrekli geni\u015flemesini vurgulamaktad\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u015eimdi Ke\u015ffedin<\/strong>: <a href=\"https:\/\/dmdwarrior.com\/clinical-trials\/\" target=\"_blank\" rel=\"noreferrer noopener\">DMDWarrioR Klinik Ara\u015ft\u0131rmalar Merkezi<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>","protected":false},"excerpt":{"rendered":"<p>For families affected by Duchenne muscular dystrophy (DMD), every new clinical development offers hope. While many promising therapies begin in the laboratory, the true test comes when they are evaluated in people. Sarcomatrix Therapeutics is now preparing to take that important step with its experimental drug S-969, announcing an ambitious roadmap that could lead to [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":8286,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[249,247,248],"class_list":["post-8284","post","type-post","status-publish","format-standard","has-post-thumbnail","category-research","tag-s-969","tag-sarcomatrix","tag-sarcomatrix-therapeutics"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/8284","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=8284"}],"version-history":[{"count":4,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/8284\/revisions"}],"predecessor-version":[{"id":8290,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/8284\/revisions\/8290"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/8286"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=8284"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=8284"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=8284"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}